Acusphere - Worst Pharma Stocks of 2007

Company: Acusphere
Starting stock price: $2.51
Ending stock price: $0.65
Percent Change: -74.10%

Details: Acusphere is focused on developing drugs using its microsphere technology. Its lead candidate is Imagify, an injectable for use during ultrasound or echocardiograms; it's designed to show perfusion, an indicator of heart disease. Its second Phase III trials of the compound were announced in May 2007 and the company is working with the FDA on a New Drug Application, which would require its manufacturing facility in Massachusetts to be certified. It expects to submit the NDA early this year.

Acusphere - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

The second of AbbVie’s highly anticipated 2019 blockbuster candidates is here: Its crucial Humira follow-up, Rinvoq.

Bristol-Myers Squibb’s takeover of Celgene hasn’t always gone smoothly, but now a once-left-for-dead centerpiece of that deal is ready to launch.

Investors sued Novo Nordisk in Denmark, claiming it misled the public about trouble plaguing its insulin franchise—and demanding $1.75B in damages.